Testen des Zusatzes eines Krebsmedikaments, BAY 1895344, zur üblichen Chemotherapie mit FOLFIRI bei fortgeschrittenem oder metastasiertem Magen- und Darmkrebs
Phase-I/Ib-Studie mit ATR-Inhibitor BAY 1895344 in Kombination mit FOLFIRI bei malignen Erkrankungen des Gastrointestinaltrakts mit Schwerpunkt auf metastasiertem Dickdarm- und Magen-/Gastroösophagealkrebs
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started (primary site) to other places in the body (metastatic). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan, fluorouracil, and leucovorin, (called FOLFIRI in short) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BAY 1895344 in combination with FOLFIRI may help shrink advanced or metastatic stomach and/or intestinal cancer.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
- Magenkrebs im klinischen Stadium III AJCC v8
- Adenokarzinom des gastroösophagealen Überganges im klinischen Stadium III AJCC v8
- Magenkrebs im klinischen Stadium IV AJCC v8
- Adenokarzinom des gastroösophagealen Überganges im klinischen Stadium IV AJCC v8
- Metastasierendes Adenokarzinom des gastroösophagealen Überganges
- Metastasierendes kolorektales Karzinom
- Darmkrebs Stadium IV AJCC v8
- Darmkrebs Stadium III AJCC v8
- Fortgeschrittenes Magenkarzinom
- Metastasierendes Karzinom des Verdauungssystems
- Metastasierendes Magenkarzinom
- Fortgeschrittenes Adenokarzinom des gastroösophagealen Überganges
- Fortgeschrittenes kolorektales Karzinom
- Fortgeschrittenes Karzinom des Verdauungssystems
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. Determine the safety and maximum tolerated dose (MTD) of elimusertib (BAY 1895344) with leucovorin calcium, fluorouracil, and irinotecan hydrochloride (FOLFIRI).
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity by overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
II. Determine the response and clinical benefit rate (complete response + partial response + stable disease) of BAY 1895344 with FOLFIRI in colorectal and gastric/gastroesophageal cancers.
III. Evaluate tumor and peripheral blood mononuclear cell (PBMC) deoxyribonucleic acid (DNA) damage signaling in the context of the chemotherapy backbone alone and when combined with BAY 1895344.
IV. Evaluate the pharmacokinetics (PK) profile of fluorouracil (5-FU) and irinotecan.
V. Evaluate the PK profile of BAY 1895344. VI. Evaluate the relationship between ATM status by immunohistochemistry (IHC) and clinical efficacy of the BAY 1895344/FOLFIRI combination.
EXPLORATORY OBJECTIVES:
I. Evaluate the exposure-response relationship between drug exposures and toxicity and response, and UGT1A1 genotype.
II. Evaluate the relationship between tumor mutations and clinical efficacy of the BAY 1895344/FOLFIRI combination.
OUTLINE: This is a dose-escalation study of elimusertib, irinotecan, and fluorouracil with fixed-dose leucovorin followed by a dose-expansion study.
Patients receive elimusertib orally (PO) once daily (QD) on days 2, 3, 16, and 17 and irinotecan hydrochloride intravenously (IV) over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study.
After completion of study treatment, patients are followed up for 30 days and then every 3 months for up to 1 year or until their disease gets worse or they begin a new treatment for their cancer.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- City of Hope Comprehensive Cancer Center
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Missouri
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Vereinigte Staaten, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Vereinigte Staaten, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Vereinigte Staaten, 63136
- Siteman Cancer Center at Christian Hospital
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Hillman Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
For Dose Escalation: Patients must have histologically or cytologically confirmed advanced or metastatic gastrointestinal (GI) cancers with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1) measurable disease who have progressed on at least one prior treatment for metastatic disease and for whom FOLFIRI is considered a reasonable treatment option. Patients with mismatch repair deficiency should have progressed on immunotherapy
-
For Dose Expansion: Patients must have either:
- Colorectal cancer who have previously progressed on irinotecan and tolerated an irinotecan dose equal to or greater than the recommended phase 2 dose (RP2D). If they have mismatch repair deficiency they should have progressed on immunotherapy OR
- Gastroesophageal cancer who have progressed on at least one first-line therapy for metastatic disease. If they have mismatch repair deficiency they should have progressed on immunotherapy
-
For Dose Expansion: Patients be willing to undergo biopsies for research purposes only. The accessible tumor can be the primary or metastatic tumor site. Both research biopsies should be taken from the same tumor site
-
Patients must have progressive disease on at least first-line therapy for metastatic disease. Previous treatment with irinotecan is allowed
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with FOLFIRI in patients <18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 1
-
Leukocytes >= 3,000/mcL
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
-
Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
-
International normalization ratio (INR) =< 1.5 × ULN unless participant is receiving anticoagulant therapy, in which case prothrombin time (PT) or activated partial thromboplastin time (aPTT) should be within expected therapeutic range of anticoagulants. If patient has a new diagnosis of venous thromboembolism (VTE), then patient should be appropriately anticoagulated with low molecular weight heparin (LMWH) or direct acting oral anticoagulants (DOACs) and be clinically stable for at least 1 week post treatment onset
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy, that does not interact with study therapy, with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy that does not interact with study therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load and HCV therapy does not interact with study therapy
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
The effects of BAY 1895344 on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors agents as well as other therapeutic agents used in this trial, 5-FU and irinotecan, are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration
- Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of study treatment administration
-
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients with a history of prior treatment with an ATR inhibitor
- Patients with a history of other malignancy that could affect compliance with the protocol or interpretation of the results
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
- Patients who are receiving any other investigational agents
- History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344, 5-FU, leucovorin, or irinotecan. Patient eligibility can be discussed with the primary investigator (PI) if prior reactions do not seem to warrant excluding the patient
- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Gastrointestinal pathology or history that adversely impact the ability to take or absorb oral medication
- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
- Patients who were unable to tolerate prior irinotecan treatment are excluded from this study
- Patients with a corrected QT (QTc) interval >= 470 msec are excluded from this study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Treatment (elimusertib, FOLFIRI)
Patients receive elimusertib PO QD on days 2, 3, 16, and 17 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo tumor biopsy
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo imaging
Andere Namen:
Given PO
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maximum Tolerated Dose (MTD) of Elimusertib (BAY 1895344) in Combination With Irinotecan, Fluorouracil, and Leucovorin (FOLFIRI)
Zeitfenster: Up to 28 days
|
A BOIN - Bayesian Optimal intervals trial design will be used to determine the MTD. |
Up to 28 days
|
|
Patients Who Experienced DLTs
Zeitfenster: Up to 28 days
|
Percentage of Patients Who Experienced Dose Limiting Toxicities (DLTs) , per CTCAE v5.0 |
Up to 28 days
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
12-month Progression-free Survival (PFS) - Total Population
Zeitfenster: At 12 months
|
Percentage of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 12 months
|
|
24-month Progression-free Survival (PFS) - Total Population
Zeitfenster: At 24 months
|
Percentage of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 24 months
|
|
Cmax of Irinotecan (Lead in)
Zeitfenster: Up to 1 year post treatment
|
Concentration Maximum (Cmax) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
AUC of Irinotecan (Lead in)
Zeitfenster: Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
AUC of 5FU (Lead-in)
Zeitfenster: Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
Cmax of Irinotecan (Combination)
Zeitfenster: Up to 1 year post treatment
|
Concentration Maximum (Cmax) of irinotecan in Combination (BAY + 5FU and Irinotecan) phase. |
Up to 1 year post treatment
|
|
AUC of Irinotecan (Combination)
Zeitfenster: Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan in Combination (BAY + 5FU and Irinotecan) phase. |
Up to 1 year post treatment
|
|
AUC of 5FU (Combination)
Zeitfenster: Up to 1 year post treatment
|
Area Under the Curve (AUC) of 5FU in Combination (BAY + 5FU and Irinotecan) phase |
Up to 1 year post treatment
|
|
Cmax of BAY 1895344
Zeitfenster: Up to 1 year post treatment
|
Concentration maximum (Cmax) of BAY 1895344. |
Up to 1 year post treatment
|
|
AUC-6 of BAY 1895344
Zeitfenster: Up to 1 year post treatment
|
Area Under the Curve of BAY 1895344. |
Up to 1 year post treatment
|
|
AUC of BAY 1895344
Zeitfenster: Up to 1 year post treatment
|
AUC of BAY 1895344 |
Up to 1 year post treatment
|
|
Overall Response Rate (ORR)
Zeitfenster: Up to 1 year post treatment
|
Percent probability of Complete Response (CR) or Partial Response (PR) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
Up to 1 year post treatment
|
|
Clinical Benefit Rate (CBR)
Zeitfenster: Up to 1 year post treatment
|
Percent probability of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters or SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters. |
Up to 1 year post treatment
|
|
Best Response
Zeitfenster: Up to 1 year post treatment
|
Number of patients with Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters or SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 1 year post treatment
|
|
Progression-free Survival (PFS) - by Dose Level
Zeitfenster: Up to 24 months post treatment
|
Median PFS will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. Measured from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 24 months post treatment
|
|
12-month Progression-free Survival (PFS) - by Dose Level
Zeitfenster: At 12 months
|
Proportion of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 12 months
|
|
24-month Progression-free Survival (PFS) - by Dose Level
Zeitfenster: At 24 months
|
Proportion of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 24 months
|
|
Progression-free Survival (PFS) - Total Population
Zeitfenster: Up to 24 months post treatment
|
Median PFS will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. Measured from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 24 months post treatment
|
|
Overall Survival (OS) - by Dose Level
Zeitfenster: Up to 24 months post treatment
|
Median number of months patients are alive from start of treatment until death while on study will be estimated within disease cohorts (KM estimator), with 95% CI. |
Up to 24 months post treatment
|
|
12- Month Overall Survival (OS) - By Dose Level
Zeitfenster: At 12 months
|
Proportion of patients alive estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of death. |
At 12 months
|
|
24-month Overall Survival (OS)
Zeitfenster: At 24 months
|
Proportion of patients alive estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of death while on study. |
At 24 months
|
|
Overall Survival (OS) - Total Population
Zeitfenster: Up to 2 years post treatment
|
Median number of months patients alive from start of treatment until death while on study will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. |
Up to 2 years post treatment
|
|
12-month Overall Survival (OS) - Total Population
Zeitfenster: At 12 months
|
Proportion of patients alive estimated by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment. |
At 12 months
|
|
24-month Overall Survival (OS) - Total Population
Zeitfenster: At 24 months
|
Proportion of patients alive estimated by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment. |
At 24 months
|
|
ATM Status
Zeitfenster: Up to 1 year post treatment
|
Will be assessed by immunohistochemistry (IHC) and PFS. The association between ATM and responses will be described, with a table outlining patients who achieved progressive disease, stable disease, partial or complete responses and whether they exhibited ATM expression by IHC or not. |
Up to 1 year post treatment
|
|
Peripheral Blood Mononuclear Cell gammaH2AX and p-ATM Signaling
Zeitfenster: Up to 1 year post treatment
|
Signaling during the pharmacokinetics (PK) lead-in and in combination with BAY 1895344 will be compared with a non-parametric paired test (e.g. Wilcoxon rank test), at a significance level at p < 0.05. For tumors, this will be performed only for patients in the dose expansion cohorts. |
Up to 1 year post treatment
|
|
Tumor Multiplex Immunofluorescence Assay Signaling
Zeitfenster: Up to 1 year post treatment
|
Signaling during the PK lead-in and in combination with BAY 1895344 will be compared with a non-parametric paired test (e.g. Wilcoxon rank test), at a significance level at p < 0.05. For tumors, this will be performed only for patients in the dose expansion cohorts. |
Up to 1 year post treatment
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Adverse Events
Zeitfenster: Up to 1 year post treatment
|
Logistic regression and proportional hazards (Cox) regression will be used to assess the relationships between exposure and response and toxicity; exposure-response will be assessed within disease cohorts of sufficient size, while exposure-toxicity will pool all patients. All patients will be used for the E-R analyses. Advanced population PK methods may be employed at a later stage to assess the link between drug exposure and biological effects and efficacy. |
Up to 1 year post treatment
|
|
Status of Deoxyribonucleic Acid Damage Repair (DDR) Genes
Zeitfenster: Up to 1 year post treatment
|
Assessed by whole exome sequencing and ribonucleic acid sequencing. The efficacy analyses will be repeated by DDR tumor mutation status, but these analyses will have limited sample sizes and will not be adequately powered for statistical comparisons. |
Up to 1 year post treatment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Liza C Villaruz, University of Pittsburgh Cancer Institute LAO
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Darmerkrankungen
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Magenerkrankungen
- Darmtumoren
- Rektale Erkrankungen
- Darmerkrankungen
- Magenneoplasmen
- Kolorektale Neubildungen
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Zytologische Techniken
- Zytodiagnose
- Physikalische Phänomene
- Camptothecin
- Alkaloide
- Enzyme und Coenzyme
- Pyrimidine
- Diagnosetechniken, chirurgisch
- Formyltetrahydrofolate
- Tetrahydrofolate
- Folsäure
- Pterins
- Pteridine
- Uracil
- Pyrimidinone
- Coenzyme
- Elektromagnetische Phänomene
- Magnetische Phänomene
- Elektromagnetische Strahlung
- Strahlung
- Strahlung, ionisieren
- Irinotecan
- Fluoruracil
- Leucovorin
- Biopsie
- Handhabung von Proben
- Röntgenaufnahmen
- Dehydroftorafur
- Bay 1895344
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCI-2020-06482
- UM1CA186690 (US NIH Stipendium/Vertrag)
- NCI-2020-06482 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- 10406 (Andere Kennung: CTEP)
- 21-060
- 10406 (Andere Kennung: UPMC Hillman Cancer Center LAO)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .